# Junta clínica — PT-pseudo_3b6ea1920967 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_3b6ea1920967",
  "pid": "PT-pseudo_3b6ea1920967",
  "task": 1,
  "psa": 6.5,
  "age": 64,
  "months": 3,
  "pirads": "4",
  "psad": 0.11,
  "psav": 1.22,
  "psap": 4.5,
  "vol": 59.14,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.7465537,
  "medhx": "Not reported",
  "meds": "None",
  "notes": "PSA 6.5 ng/mL. PI-RADS 4. PSAD 0.11. Prostate volume 59 mL. csPCa 0.75.",
  "pmhx": [],
  "allergies": [],
  "vitals": {
    "weight": "70 kg",
    "height": "174 cm",
    "bmi": "23.1",
    "bp": "146/61 mmHg",
    "hr": "63 bpm",
    "smoking": "Ex-smoker (38 pack-yr, quit 2007)",
    "last_dental": "6 mo ago",
    "flu_vax": "Nov 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "11 Jan 2025",
  "enc_ref": "Dr. K. Bakker (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical assessment required due to a prior prostate cancer diagnosis coupled with a recent PSA increase to 6.5 ng/mL."
    },
    {
      "s": "History",
      "t": "A 64-year-old retired primary school teacher initially came to medical attention for an incidental PSA rise in early 2023 and has since remained under surveillance after his first positive biopsy. He is widowed and shares his home with a long-term partner, enjoying an active routine that features weekend hiking alongside moderate alcohol intake of roughly four units weekly. He reports moderate lower urinary tract symptoms scoring 13 on the IPSS, while explicitly denying hematuria, bone pain, or unexplained weight loss. His smoking history includes 38 pack-years, having ceased consumption in 2007. He maintains a residence situated over ninety minutes from the clinic and has expressed a preference for telephone follow-ups when clinically suitable, having recently finished a baseline memory clinic screening and a standard audiology assessment."
    },
    {
      "s": "Physical examination",
      "t": "DRE — texture: smooth and firm; mobility: unrestricted; asymmetry: absent. The gland presents as symmetrically enlarged without palpable nodules. General examination remains unremarkable, with stable vital signs, clear lung fields, and a regular cardiac rhythm. Peripheral lymphadenopathy and abdominal masses are notably absent."
    }
  ],
  "occupation": "retired primary school teacher",
  "marital": "Widowed",
  "living": "Lives with partner",
  "next_of_kin": "Spouse / partner (primary contact)",
  "recent_other": [
    "Audiology — hearing test",
    "Memory clinic — baseline screening"
  ],
  "alcohol": "4 units / week",
  "exercise": "Hiking on weekends",
  "ipss": "IPSS score: 13/35 (moderate LUTS)",
  "admin": "Lives >90 min from clinic; phone follow-up preferred where clinically safe.",
  "mri_hospital": "Erasmus MC",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_3b6ea1920967
Task: 1

Encounter: Urology - outpatient on 11 Jan 2025.
Referrer: Dr. K. Bakker (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 64-year-old male
  - PSA: 6.5 ng/mL
  - mpMRI — PI-RADS score: 4 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.11 ng/mL²
  - PSA velocity: 1.22 ng/mL/yr
  - Prior PSA: 4.5 ng/mL
  - Prostate volume: 59.14 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.7465537 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Not reported
  - Problem list / PMHx: none recorded
  - Current medication: None
  - Allergies: NKA
  - Additional notes: PSA 6.5 ng/mL. PI-RADS 4. PSAD 0.11. Prostate volume 59 mL. csPCa 0.75.

Vitals: weight 70 kg, height 174 cm, BMI 23.1, BP 146/61 mmHg, HR 63 bpm. Smoking: Ex-smoker (38 pack-yr, quit 2007).

Chief complaint: Clinical assessment required due to a prior prostate cancer diagnosis coupled with a recent PSA increase to 6.5 ng/mL.

History: A 64-year-old retired primary school teacher initially came to medical attention for an incidental PSA rise in early 2023 and has since remained under surveillance after his first positive biopsy. He is widowed and shares his home with a long-term partner, enjoying an active routine that features weekend hiking alongside moderate alcohol intake of roughly four units weekly. He reports moderate lower urinary tract symptoms scoring 13 on the IPSS, while explicitly denying hematuria, bone pain, or unexplained weight loss. His smoking history includes 38 pack-years, having ceased consumption in 2007. He maintains a residence situated over ninety minutes from the clinic and has expressed a preference for telephone follow-ups when clinically suitable, having recently finished a baseline memory clinic screening and a standard audiology assessment.

Physical examination: DRE — texture: smooth and firm; mobility: unrestricted; asymmetry: absent. The gland presents as symmetrically enlarged without palpable nodules. General examination remains unremarkable, with stable vital signs, clear lung fields, and a regular cardiac rhythm. Peripheral lymphadenopathy and abdominal masses are notably absent.

Patient info: retired primary school teacher; Widowed; Lives with partner.
Next of kin: Spouse / partner (primary contact).

Lifestyle: alcohol 4 units / week; exercise Hiking on weekends; IPSS score: 13/35 (moderate LUTS).

Recent other appointments: Audiology — hearing test; Memory clinic — baseline screening.
Admin: Lives >90 min from clinic; phone follow-up preferred where clinically safe.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-CLASSIFIER

*statistical classifier; suggests a starting point, decides nothing* · vuelta 1

A classifier trained only to open the discussion, not to close it. Here is its bid.

SUGGESTION: BIOPSY   p(biopsy) = 0.66
  uncertainty  +/- 0.16 (95% CI 0.34-0.97); among patients it cannot tell apart the outcome was 0.93 of 1.00 mixed
  confidence   LOW — in this tier it was right 49% of the time over 43 labelled cases — barely better than a coin, so treat it as an opening bid and nothing more

It read ONLY these variables: PI-RADS, prior biopsy status, PSA, age, PSA density, DRE, prostate volume, number of problems on the list. Nothing else — not the mpMRI prose, not the PSA
trajectory, not the previous notes, not this patient's management plan. Values it could not
read for this patient: none.
Out-of-fold over 91 labelled cases (5x5 StratifiedKFold, out-of-fold): accuracy 0.714 against a
majority-class baseline of 0.615, AUC 0.789, F1(yes) 0.78.

The final call is the senior urologist's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. I have no answer for him, and that is the finding.

The criterion here is that the visible panel does not determine this decision: the man already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. Measured on the 49 labelled cases in this
situation: no structured variable separates the two answers — PSA is rising in all 49 — the
split is 26 defer / 23 biopsy, and every rule fitted on one half failed on the other.

Do not read this as 'defer' and do not read it as 'biopsy'. It means the panel cannot settle
this man and the retrieved documents have to.

## Intervención 5 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The guideline suggests that a stable MRI (PRECISE 1-3) with a low PSA-D (< 0.15) may lead to omitting a repeat biopsy in patients with low-risk disease. It also notes that a PSA change alone should not change management based on its weak link with grade progression.

WHAT THE CLASSIFIER'S BID DOES NOT SETTLE
The classifier's suggestion of biopsy is not sufficiently informed by the guideline because it fails to account for the specific threshold for low-risk disease, such as the PSA density threshold of 0.15. It also cannot weigh the clinical context of the prior positive biopsy against the current PI-RADS 4 finding in the context of the guideline's recommendations for when to omit a repeat biopsy.

WHAT WE STILL NEED
The mpMRI prose - The mpMRI prose does not compare against an earlier study. The guideline does not specify what is required for this patient.
PSA history - The PSA history shows a rise from 4.5 to 6.5 ng/mL over 3 months, which is a variable that the guideline makes decisive that the classifier could not read.
Previous notes - The previous notes state the prior biopsy was positive, which is a fact that the guideline makes decisive that the classifier could not read.
Laboratory results - The PSA density of 0.11 ng/mL² is a variable that the guideline makes decisive that the classifier could not read.

## Intervención 6 — MODERATOR

*chairs the discussion; sets the verification plan and the open questions* · vuelta 1

This case hinges on whether the rising PSA and the specific PSA density value, in the context of a prior positive biopsy and a PI-RADS 4, warrant a repeat biopsy according to the EAU guidelines.

Before anyone argues, this is what I want established, and by whom.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Determine if the mpMRI prose compares the current findings against an earlier study.
  psa_trend (get_psa_trend) -> Confirm the full PSA history to fully assess the rate and pattern of the rise.
  previous_notes (get_previous_notes) -> Confirm the management context, specifically the finding of the prior positive biopsy.

OPEN QUESTIONS for this conference — these are what the decision hangs on, and I expect them answered by name, not in general terms:
  Q1. What does the mpMRI prose state regarding comparison against an earlier study?
  Q2. How should the rising PSA trend (4.5 to 6.5 ng/mL over 3 months) be weighted against the guideline recommendations?

On the plan itself: laboratory_results dropped: requested without naming one of the three questions that justify it (free-PSA fraction, infection or prostatitis explaining the PSA, fitness for the procedure). The DRE and the headline PSA are already on the panel.

## Intervención 7 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report
The mpMRI prose states: "Re-evaluation of prior prostate cancer diagnosis. Current PSA 6.5 ng/mL. Previous PI-RADS 4 lesion identified." It does not explicitly state whether the current PI-RADS 4 lesion compares against an earlier study.

psa_trend
The full PSA history shows values: {"date": "Jan 2023", "val": 2.1}, {"date": "Sep 2023", "val": 3.1}, {"date": "May 2024", "val": 4.5}, {"date": "Jan 2025", "val": 6.5}. This confirms a rise from 4.5 ng/mL to 6.5 ng/mL over 3 months.

previous_notes
The previous notes confirm the management context: "During a consultation on 13 Sep 2024, Dr. K. Bakker (GP) documented a PSA escalation from 4.5 ng/mL recorded in May 2024 to 5.1 ng/mL at that visit. In light of the patient's history of a prior positive biopsy alongside this upward trajectory, a follow-up PSA was requested; the subsequent result of 6.5 ng/mL triggered this urology referral for clinical assessment."

WHAT I DID NOT OPEN
laboratory_results. I deliberately left this closed because the moderator stated that the laboratory results were requested without naming a specific question that justified it, and I am restricted to only reporting what the moderator asked for.

WHAT THIS SUPPORTS
FOR sampling this patient now
The rising PSA trend (4.5 to 6.5 ng/mL over 3 months) is a variable that the EAU guideline makes decisive that the classifier could not read.
The previous notes confirm the management context, specifically the finding of the prior positive biopsy.

AGAINST sampling this patient now
nothing

WHERE THIS LEANS
The data confirms the variables the EAU guideline highlighted as decisive, specifically the rising PSA trend and the prior positive biopsy status.
LEAN: biopsy

## Intervención 8 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The registrar has answered Q1 by stating the mpMRI prose does not explicitly state whether the current PI-RADS 4 lesion compares against an earlier study.

ALIGNMENT WITH THE CLASSIFIER
The retrieved evidence aligns with the EXPERT-CLASSIFIER's suggestion of BIOPSY because the registrar noted that the rising PSA trend and the prior positive biopsy status are variables that the EAU guideline makes decisive, which supports the initial suggestion.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What does the mpMRI prose state regarding comparison against an earlier study? Answered by the REGISTRAR, who stated it does not explicitly state whether the current PI-RADS 4 lesion compares against an earlier study.
Q2. How should the rising PSA trend (4.5 to 6.5 ng/mL over 3 months) be weighted against the guideline recommendations? Answered by the REGISTRAR, who noted this trend is a variable the EAU guideline makes decisive.

WHAT CARRIES WEIGHT, AND WHY
The two most relevant variables are the rising PSA trend because the guideline makes this decisive, and the prior positive biopsy status because it confirms the management context. The PSA density (0.11 ng/mL²) is also relevant as it is a variable the guideline makes decisive, though the specific justification for its inclusion is not detailed here. The guideline does not explicitly support any variable the room has been leaning on, as the cohort showed no clear separation based on the panel alone.

MY SUGGESTION TO THE CHAIR
I suggest proceeding with a biopsy, as the retrieved evidence confirms the presence of key factors—rising PSA trend and prior positive biopsy—that the guideline deems significant enough to warrant further investigation.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 9 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: clear)

I recommend biopsy because the rising PSA trend from 4.5 to 6.5 ng/mL over three months and the prior positive biopsy status are key factors the EAU guideline deems significant. Although the patient has a known diagnosis, the documented trajectory and prior tissue result provide the necessary context to determine if further sampling changes the management pathway. The room converged on proceeding with a biopsy based on these retrieved findings.

What carried weight: bx=important, age=important, psa=important, vol=noted, psad=important, cspca=noted, pirads=important, comorbidity=noted
Documents this conference opened: radiology_report, psa_trend, previous_notes
